Clinical Trial Update: JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study [Phase 1]

View source ↗

Summary

Phase Ib study evaluating JS014 in combination with toripalimab and transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• JS014
• Toripalimab (Toripalimab)

Snippet

Sponsor: Xiangya Hospital of Central South University | Conditions: Hepatocellular Carcinoma (HCC) | Phase 1 | Status: ENROLLING_BY_INVITATION